54

194

~~~~IN-RELEA~~G PEPTIDE (GRP) AND PRO- GAsTRm-REmAsmG PEPTIDE (PRO-GRP) NEA- SURED IN THE PLASMA OF 169 PATIENTS WITH

S%ALL CELr T,UNG CANCER (SCLC) .L.Drivsholm'and #- J.J.Holst. Department of Oncology,Rigshospi-

talet,Copenhagon,Denmark'and Institute of GYP- dicnl Physiology C,University of Copenhagen! Plasma from 169 patients with SCLC were ITL(?~T,UT -ed Cor GBP and pro-GRP before treatment;and a number of patients had samples measured during treatnent.The concentration in plasma from normal subjects (n=27)has been neasured,earli- er,and values were all below 10 pmol/l and the mean concentration of pro-GRP and GRP was 3 and 2,reopectively.The 169 patients (ags=35-70 ) were "staged" as having either local disease (LD),n=7V,or extensive disease (ED),n=VO.For the group of patients with LD,Vl% had pro-GRP values above 10 pmol/l and the median value was 22 (range=8-144).GRP was nuch rarer eleva- ted with a median value of 4 (range=O-31).In patients with ED,V3% had pro-GRP values above 10 pnol/l.IIowaver;the median value 1~~s 33(ran- ge=7-512);and GRD was much lower (median=7,5, range=1_233).During treatment a number of pa- tients had/have blood samples taken, and the first results from 7 patients "follolrad-to- death" show pro-GRP and to a lesser degree G?.? values paralleling the clinical response.Chan-. ges have been neasursd up to 5 weeks earlier than the changes could be seen on the X-ray. More results will be presented.Pro--GRP seems like a pronissing tumor marker for SCLC-pts.

al I

1%

Epiderml growth factor (ECF) in non-sn cell lung cancer - correlation with survival.

AKIHIKO ISHIKURO,HIROSHI MIYhHOTO,HIROTOSH 1 hKITA,HITOSHI HANEDA.HICHIHIRO FUJINO. MASAKAZU KATOU.YOSHIKAZU KAWAKAMI First Dept.of Hed.. School of Hed.,

Hekkaido Univ..Japan

The expression of epidernal grouth factor

(EGF) in non-small cell lung cancer(NSCLC)

was studied.

Sixty-one surgically resected NSCLC(37 adeno-

carcinomas and 24 squamous cell carcinomas)

were analyzed. Deparaffinized sections were

stained immunohistochemically using anti ECF

rabbit serum( Wakunaga Pharmaceutical Co.Ltd.1

by the avidin-biotin peroxidase complex method

( Vectastain ABC kit). The inmunoreactivity of

tumor cells and stromal fibroblasts was examined

and separated into 2 grades; intense(hisb) and

meak/negative(low). High reactions mere observed

in 661 of the tumor cells and 20X of the.

fibrohlasts. Regional node involvement was

observed less frequently in the group showing

low immunoreactions in both tumor cells and

fihroblasts( 332) than the ather group( 63X,

p<O.O5). The former group had longer survival

times( a five year survival ratio of 672) than the latter group( 312). The ECF inmunoreactivity

may help to predict the patient’s prognosis.

1%

CROMOGRANIN A, A POSSIBLE TUMOR MARKSR IN

PaleoheimoS SMALL CELL LUNG CANCER.SL.Drivsholmy L.I.

cclog~l; and Dekt"E: ~i~~n~~,mp~p~T~~~~:p~~a~n- let, Denmark; and DAK0 A/S, DEN?WRK? A few contradictory results regarding the gly- coprotein Cromogranin A in the blood of pa- tients with small cell lung cnncer (SCLC)have been published.In order to evaluate the pas-- sible value as a tumor marker,Cromogranin .A was measured by an ELISA-technique in the plasnn of 140 patients (age 35-70) \Iith SCT,C. Healthy persons (n=28) had a mean value of 0, 76 nnol/l (SD=0,18;range=o,46--l,lo;median=O,76 ).Values beyond maan+2SD (=1,12)wero consider- ed to be abnormally high.The pIean value nf pn- tients (n=77) with limited disease (SD) x/as 1, 05 nmol/l (SD=0,8V;range=0,28-6,33~median=O,81 1 and 31% had elevated values (p=0,24V).The mean value of patients (n=63) with extensive disease (ED) was 1,59 nmol/l (SD=1,52;range-0, 23-V.O8;median=1,41)and 44% had elevated valu- es (p=0,015).The mean concentration in ED was significant higher than in ;D (p=0,048).All P- values are calculated by the Mann-Whitney tent .A11 13 patients with histological-proven bonemarrow and liver metastasis had elevated values, and by including the 3 patients with histological-proven bonemarrow metastasis out only ultrasound..proven liver metastasis,818 had elevated values (13/16).

Cronogranin A night be a possi:>le t.umor marker in a group of patients with SCLC.

197

Clinicopathological study of malignant tumor of the thymus (invasive thymcma,thymic carcinana and thymic carcinoid)

Jun SHINADA,M.D.,Hirokuni YOSHIMURA,M.D.,Akira ISHIHARA,M.D.,*Kiyoshi KASAI,M.D.,%ru KAMEYA,M.D. Department thoracic surgery, *Department of pathology Kitasato University,School of Medicine,Kanagawa,Japan

The subjects are 27 patients with nonteratmatms malignant tumor of the thyms, which were seen at Kitasato University Hospital. 16 were invasive thym- ms, 9 were thymic carcinomas and 2 were thymic carcinoids. 5 patients with thymic carcinana(55%) died of tumor following radiation at three to fifteen months. And one patient with thymic carcinoid(50%) died of tumor at eleven years after resection. Eut only two patients with invasive thymma(12B) died of tmmr at six months and nine years. There were association between survival and patholog- ical featurs. DNA contents, and number or size of nucleolar organ- zer resions using a silver staining technique in the nucleus of a tumor cell were useful of differentiation fran thymcma and thymic carcinaM.